Search for “lymphoma”
Search results
-
Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma.
Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma. Journal Hematol …
-
Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
… to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have …
-
DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features.
DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features. …
-
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.
… Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. Journal …
-
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.
… of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Journal …
-
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.
… untreated, transplant-ineligible patients with mantle cell lymphoma. Journal Blood Adv. …
-
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda
… of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future …
-
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.
… untreated, transplant-ineligible patients with mantle cell lymphoma. Journal Blood Adv, …
-
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.
… of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Journal …
-
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool.
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an …
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.